Recent Investment Analysts’ Ratings Updates for AbbVie (ABBV)

Several analysts have recently updated their ratings and price targets for AbbVie (NYSE: ABBV):

  • 2/2/2018 – AbbVie had its price target raised by analysts at Argus from $120.00 to $145.00. They now have a “buy” rating on the stock.
  • 2/2/2018 – AbbVie was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 1/30/2018 – AbbVie had its price target raised by analysts at Morgan Stanley from $99.00 to $131.00. They now have an “equal weight” rating on the stock.
  • 1/29/2018 – AbbVie had its “buy” rating reaffirmed by analysts at Evercore ISI. They now have a $144.00 price target on the stock.
  • 1/29/2018 – AbbVie was given a new $135.00 price target on by analysts at Credit Suisse Group AG. They now have a “hold” rating on the stock.
  • 1/29/2018 – AbbVie was downgraded by analysts at BMO Capital Markets from a “market perform” rating to an “underperform” rating. They now have a $84.00 price target on the stock, down previously from $125.86. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 1/29/2018 – AbbVie had its price target raised by analysts at SunTrust Banks, Inc. to $157.00. They now have an “average” rating on the stock.
  • 1/29/2018 – AbbVie was downgraded by analysts at Leerink Swann from an “outperform” rating to a “market perform” rating. They now have a $127.00 price target on the stock.
  • 1/26/2018 – AbbVie had its price target raised by analysts at Piper Jaffray Companies from $115.00 to $130.00. They now have an “outperform” rating on the stock.
  • 1/22/2018 – AbbVie was given a new $98.00 price target on by analysts at Credit Suisse Group AG. They now have a “hold” rating on the stock.
  • 1/22/2018 – AbbVie was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “AbbVie’s key drug Humira has been performing well based on strong demand trends for the drug, despite new competition. Moreover, Imbruvica has multibillion dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. AbbVie’s shares outperformed the industry in the past one year supported by a series of positive news including promising data from several pivotal studies, regulatory approvals in the U.S., Europe, and Japan for its competitive HCV medicine Mavyret and FDA approval for the sixth indication for Imbrivica and settlement of its Humira patent disputes with Amgen. Also, several pivotal data readouts and regulatory milestones are expected in 2018. However, HCV sales continue to be hurt by intensifying competition. Estimates have gone up slightly ahead of the Q4 earnings release. AbbVie has a positive record of earnings surprises in the recent quarters.”
  • 1/18/2018 – AbbVie was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $115.00 price target on the stock. According to Zacks, “AbbVie’s key drug Humira has been performing well based on strong demand trends for the drug, despite new competition. Moreover, Imbruvica has multibillion dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. AbbVie’s shares outperformed the industry in the past one year supported by a series of positive news including promising data from several pivotal studies, regulatory approvals in the U.S., Europe, and Japan for its competitive HCV medicine Mavyret and FDA approval for the sixth indication for Imbrivica and settlement of its Humira patent disputes with Amgen. Also, several pivotal data readouts and regulatory milestones are expected in 2018. However, HCV sales continue to be hurt by intensifying competition. Estimates have remained stable ahead of the Q4 earnings release. AbbVie has a positive record of earnings surprises in the recent quarters.”
  • 1/11/2018 – AbbVie was given a new $84.00 price target on by analysts at BMO Capital Markets. They now have a “hold” rating on the stock.
  • 1/8/2018 – AbbVie was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $113.08 price target on the stock.
  • 1/5/2018 – AbbVie was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “AbbVie’s key drug Humira has been performing well based on strong demand trends for the drug, despite new competition. Moreover, Imbruvica has multibillion dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. AbbVie’s shares outperformed the industry in 2017 supported by a series of positive news including promising data from several pivotal studies, regulatory approvals in the U.S., Europe, and Japan for its competitive HCV medicine Mavyret and FDA approval for the sixth indication for Imbrivica and settlement of its Humira patent disputes with Amgen. Also, several pivotal data readouts and regulatory milestones are expected in 2018. However, HCV sales continue to be hurt by intensifying competition. Estimates have remained stable ahead of the Q4 earnings release. AbbVie has a positive record of earnings surprises in the recent quarters.”
  • 1/4/2018 – AbbVie had its price target raised by analysts at Jefferies Group LLC from $115.00 to $120.00. They now have a “buy” rating on the stock.
  • 1/2/2018 – AbbVie had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies.
  • 1/2/2018 – AbbVie was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $108.00 price target on the stock. According to Zacks, “AbbVie’s key drug Humira has been performing well. At the Q3 earnings call, AbbVie raised its long-term target for Humira sales based on strong demand trends for the drug, despite new competition. Moreover, Imbruvica has multibillion dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. Meanwhile, the past 2-3 months have been strong for the company as it presented promising data from several pivotal studies, gained regulatory approvals in the U.S., Europe, and Japan for its competitive HCV medicine Mavyret and FDA approval for the sixth indication for Imbrivica and settled its Humira patent disputes with Amgen. Also, several pivotal data readouts and regulatory milestones are expected in 2018. AbbVie’s shares outperformed the industry in 2017. However, HCV sales continue to be hurt by intensifying competition.”
  • 12/20/2017 – AbbVie was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $113.08 price target on the stock.
  • 12/20/2017 – AbbVie was given a new $84.00 price target on by analysts at BMO Capital Markets. They now have a “hold” rating on the stock.

AbbVie Inc (NYSE:ABBV) traded up $1.07 during trading hours on Monday, reaching $112.37. The company’s stock had a trading volume of 3,482,390 shares, compared to its average volume of 7,365,466. AbbVie Inc has a 12 month low of $60.15 and a 12 month high of $125.86. The company has a debt-to-equity ratio of 5.08, a current ratio of 1.45 and a quick ratio of 1.32. The stock has a market capitalization of $178,750.00, a P/E ratio of 27.27, a P/E/G ratio of 1.06 and a beta of 1.61.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, January 26th. The company reported $1.48 EPS for the quarter, beating the Zacks’ consensus estimate of $1.44 by $0.04. AbbVie had a return on equity of 152.78% and a net margin of 18.82%. The company had revenue of $7.74 billion for the quarter, compared to the consensus estimate of $7.53 billion. During the same quarter in the previous year, the business earned $1.20 earnings per share. The company’s revenue for the quarter was up 13.9% on a year-over-year basis. equities analysts expect that AbbVie Inc will post 7.46 EPS for the current year.

In other AbbVie news, SVP Timothy J. Richmond sold 87,040 shares of AbbVie stock in a transaction on Monday, December 18th. The stock was sold at an average price of $98.45, for a total value of $8,569,088.00. Following the sale, the senior vice president now owns 113,118 shares in the company, valued at $11,136,467.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Laura J. Schumacher sold 145,510 shares of AbbVie stock in a transaction on Friday, December 15th. The shares were sold at an average price of $96.71, for a total value of $14,072,272.10. The disclosure for this sale can be found here. Insiders sold 450,743 shares of company stock worth $43,153,684 in the last 90 days. Company insiders own 0.23% of the company’s stock.

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Receive News & Ratings for AbbVie Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply